Your browser doesn't support javascript.
loading
Extremely low warfarin dose in patients with genotypes of CYP2C9*3/*3 and VKORC1-1639A/A / 中华医学杂志(英文版)
Chinese Medical Journal ; (24): 2767-2770, 2011.
Article in English | WPRIM | ID: wpr-292808
ABSTRACT
<p><b>BACKGROUND</b>Patients with the genotypes of both CYP2C9*3/*3 and VKORC1-1639 A/A are expected to require the lowest dose of warfarin, and to have a greatly increased risk of bleeding. The experience for the dosing of warfarin in such extremely rare cases has been seldom reported.</p><p><b>METHODS</b>Demographic and clinical data from two cases with stable low dose of warfarin in China were studied by resequencing the corresponding gene segments in their whole blood DNA. The potential clinical value of the pharmacogenetic algorithm for them was evaluated by calculating the stable dose of warfarin in pharmacogenetic algorithm developed by International Warfarin Pharmacogenetics Consortium.</p><p><b>RESULTS</b>Both cases (68-year-old female and 50-year-old male) were diagnosed as chronic nonvalvular atrial fibrillation needing warfarin treatment, with target international normalized ratio (INR) 2 to 3. Case 1 had stable warfarin dose of 0.625 mg/d and case 2 1.25 mg/d. They needed more than 1 month to stabilize their anticoagulation. Exceeding INR values were recorded for them when the dose of warfarin was no more than 2 mg/d. Hemorrhagic complication appeared in case 1 when the dose was titrated from 2.5 to 1.25 mg/d. No concomitant medicine to increase or decrease the INR value was recorded for them. Genotyping CYP2C9 and VKORC1 showed both patients were the carriers of the homozygous alleles -CYP2C9*3/*3 and VKORC1-1639 A/A. Their stable doses of warfarin calculated by the pharmacogenetic dose algorithm (0.672 mg/d for case 1 and 1.16 mg/d for case 2) were comparable with their actual stable therapeutic doses.</p><p><b>CONCLUSIONS</b>Two Chinese with the rare genotypes of both CYP2C9*3/*3 and VKORC1-1639 A/A were found to require the extremely low dose of warfarin. The pharmacogenetic algorithm incorporating the variances of VKORC1 and CYP2C9 genotypes, as well as the non-genetic factors could predict their stable dose of warfarin with high accuracy.</p>
Subject(s)
Full text: Available Index: WPRIM (Western Pacific) Main subject: Pharmacogenetics / Warfarin / Aryl Hydrocarbon Hydroxylases / Vitamin K Epoxide Reductases / Cytochrome P-450 CYP2C9 / Genetics / Genotype / Hemorrhage / Mixed Function Oxygenases / Anticoagulants Type of study: Prognostic study Limits: Aged / Female / Humans / Male Language: English Journal: Chinese Medical Journal Year: 2011 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Pharmacogenetics / Warfarin / Aryl Hydrocarbon Hydroxylases / Vitamin K Epoxide Reductases / Cytochrome P-450 CYP2C9 / Genetics / Genotype / Hemorrhage / Mixed Function Oxygenases / Anticoagulants Type of study: Prognostic study Limits: Aged / Female / Humans / Male Language: English Journal: Chinese Medical Journal Year: 2011 Type: Article